Key result
Percutaneous dilatation of renal artery stenosis improved peripheral endothelial function and systolic blood pressure in bilateral disease, but did not change coronary flow reserve.
Why the study?
Does percutaneous dilatation of renal artery stenosis improve coronary flow reserve and peripheral endothelial function in patients with atherosclerotic renovascular disease?
Observational (n=19)
Does percutaneous dilatation of renal artery stenosis improve coronary flow reserve and peripheral endothelial function in patients with atherosclerotic renovascular disease?
Percutaneous dilatation of bilateral renal artery stenosis improves peripheral endothelial function and reduces left ventricular mass, but does not affect coronary flow reserve.
Answers are grounded in this paper and cite their sources.
Renal artery dilatation may improve endothelial function in bilateral disease; leaves open effects on coronary flow reserve and needs prospective validation.
BACKGROUND: Patients with atherosclerotic renovascular disease (ARVD) are at increased risk of heart disease because of associated hypertension, coronary artery disease, cardiac failure and chronic kidney disease. Although suggested to be beneficial, the cardiac effects of renal artery revascularization have not been well characterized. Our aim was to analyze the effects of percutaneous dilatation of renal artery stenosis (RAS) in ARVD patients on coronary and peripheral vascular function. METHODS: Nineteen ARVD patients [11 females and 8 males, age at study entry (mean ± SD) 69 ± 10 years] were treated by dilatation of unilateral (n = 9) or bilateral (n = 10) RAS, mainly because of uncontrolled or refractory hypertension. The patients were studied before and after the procedure (103 ± 29 days). They underwent echocardiography and peripheral artery endothelial function testing using flow-mediated dilatation (FMD) of brachial artery at rest and during reactive hyperemia. Myocardial blood flow was measured using quantitative PET perfusion imaging at baseline and during dipyridamole-induced hyperemia. RESULTS: Peripheral endothelial function, tested by FMD, as well as systolic blood pressure and left ventricular mass were improved in patients with bilateral RAS. However, myocardial perfusion and coronary flow reserve (CFR) did not change after the RAS dilatation. CONCLUSION: This is the first study to analyze the stage of myocardial perfusion and CFR in ARVD patients. Although peripheral endothelial function, systolic blood pressure and left ventricular hypertrophy were improved in patients with bilateral RAS by revascularization of RAS, it did not have any effect on coronary perfusion.
No takes yet. Share an insight, caveat, or question.
Koivuviita et al. (2010) conducted an observational in Atherosclerotic renovascular disease (ARVD) (n=19). Percutaneous dilatation of renal artery stenosis vs. Baseline (before procedure) was evaluated on Coronary flow reserve and peripheral endothelial function. Percutaneous dilatation of renal artery stenosis improved peripheral endothelial function and systolic blood pressure in bilateral disease, but did not change coronary flow reserve.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: